Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.

Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.

Item
http://www.wikidata.org/entity/Q39371874
Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomasRole of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphomaCombination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcomaB7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.Immune checkpoint inhibition in lymphoid disease.Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?MYC: Master Regulator of Immune Privilege.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.Effect of dihydroarteminin combined with siRNA targeting Notch1 on Notch1/c-Myc signaling in T-cell lymphoma cells.
P2860

Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.

Item
http://www.wikidata.org/entity/Q39371874
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@en
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@nl
type
label
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@en
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@nl
prefLabel
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@en
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@en
P2093
P2860
P304
P31
P356
10.3109/10428194.2012.673228
P433
P478
P577
P698